Berlin, Berlin, Germany
Eric Guenzi is a dynamic biopharma executive celebrated for his exceptional leadership in advancing biologics and biosimilars. As the CEO of UGA Biopharma, Eric has propelled the company to the forefront of innovation by spearheading the development of cutting-edge monoclonal cell lines and custom CHO cell culture systems. His visionary approach has not only driven successful clinical trials but also secured pivotal market approvals for these breakthrough products. Before his tenure at UGA Biopharma, Eric excelled as Vice President at Alvotech, where he played a key role in the development and regulatory success of high-impact biosimilars, including adalimumab and ustekinumab. His extensive expertise encompasses managing state-of-the-art GLP/GMP facilities and navigating intricate regulatory submissions, showcasing his adeptness at overcoming complex regulatory hurdles and achieving market readiness. With a Ph.D. in Molecular Genetics and a robust blend of industry and academic experience, Eric’s career is marked by his ability to ignite scientific innovation, attract substantial funding and investors, and deliver transformative regulatory and research achievements. Specialties: Biologic and Biosimilar development, strategic regulatory submissions (EMA, FDA), leadership in GLP/GMP facilities, advanced preclinical and analytical development, innovative patents and intellectual property, strategic project management, cutting-edge monoclonal antibody production, securing major grants and funding, pioneering immunology research, and effective scientific advisory and collaboration.
UGA Biopharma was established in 2009 in Hennigsdorf near Berlin, Germany. The company‘s international team of experts specializes in the development of monoclonal cell lines for the manufacture of biologics and biosimilars. Alongside our ready-to-use (R2U) cell lines for the expression of biosimilar candidates, our customized First CHOice® feed and media platform for cell cultures provides you with a wide range of options. UGA Biopharma supports you all the way, from cell line development and bioprocess drafting down to designing purification and analysis processes. We tailor our services to meet your specific requirements and deliver customized solutions of the highest quality. Our customers have used products from UGA Biopharma in several clinical studies and obtained relevant market approvals.
Responsible of the Analytical and Preclinical development of all Biosimilar therapeutic Antibodies / Recombinant proteins in Alvotech pipeline Clinical Indications: Rheumatoid arthritis/ Multiple Sclerosis/ Morbus Crohn / Psoriasis / Autoimmune diseases / Oncology
Co-founder of Baliopharm. Oversee development and project managment of all drug candidates Therapeutic Antibody / Recombinant protein Autoimmune diseases / Oncology
Preclinical development and project management of all drug candidates Therapeutic antibody and Recombinant protein Autoimmune diseases / Oncology / Immunology
Autoimmune disease / Oncology / Immunology